We retrospectively administered a breakpoint-specific qPCR design for screening for the most frequent types of IKZF1 deletions to 78 ALL patients that were diagnosed and treated between 2010 and 2022. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.